[go: up one dir, main page]

AU5068999A - Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier - Google Patents

Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier

Info

Publication number
AU5068999A
AU5068999A AU50689/99A AU5068999A AU5068999A AU 5068999 A AU5068999 A AU 5068999A AU 50689/99 A AU50689/99 A AU 50689/99A AU 5068999 A AU5068999 A AU 5068999A AU 5068999 A AU5068999 A AU 5068999A
Authority
AU
Australia
Prior art keywords
gene
lipid
drug carrier
emulsion
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50689/99A
Inventor
Hesson Chung
Seo Young Jeong
Ick Chan Kwon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Science and Technology KIST
Original Assignee
Korea Institute of Science and Technology KIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Science and Technology KIST filed Critical Korea Institute of Science and Technology KIST
Publication of AU5068999A publication Critical patent/AU5068999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU50689/99A 1998-07-31 1999-07-30 Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier Abandoned AU5068999A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19980031249 1998-07-31
KR9831249 1998-07-31
PCT/KR1999/000414 WO2000006120A1 (en) 1998-07-31 1999-07-30 Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier

Publications (1)

Publication Number Publication Date
AU5068999A true AU5068999A (en) 2000-02-21

Family

ID=19546046

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50689/99A Abandoned AU5068999A (en) 1998-07-31 1999-07-30 Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier

Country Status (5)

Country Link
EP (1) EP1100464A1 (en)
JP (1) JP2002521423A (en)
KR (1) KR100374482B1 (en)
AU (1) AU5068999A (en)
WO (1) WO2000006120A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512599A (en) 1998-12-30 2003-10-31 Dexcel Ltd Formulation for cyclosporin administration featuring a hydrophilic solvent and a surfactant with a HLB of less than 5
JP2002537102A (en) * 1999-02-26 2002-11-05 カイロン コーポレイション Microemulsion with adsorbed polymer and fine particles
MXPA01011660A (en) * 1999-05-20 2004-04-05 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response.
US7153525B1 (en) 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
EP1355670A2 (en) * 2000-04-20 2003-10-29 University of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane destabilisers
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
JP2001300287A (en) * 2000-04-20 2001-10-30 Nof Corp Perfluorocarbon emulsion formulation
KR100618033B1 (en) * 2004-06-21 2006-08-30 에이엔에이치 케어연구소(주) External preparation composition for the treatment of atopic diseases containing doxepine hydrochloride as an active ingredient
PL1940439T3 (en) 2005-08-11 2011-04-29 Univ Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine
US8530436B2 (en) 2007-01-29 2013-09-10 Transderm, Inc. Methods and compositions for transdermal delivery of nucleotides
CA2578647A1 (en) * 2007-02-15 2008-08-15 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine
WO2009149418A2 (en) 2008-06-06 2009-12-10 Asuragen, Inc. Novel compositions for the in vivo delivery of rnai agents
GB0901857D0 (en) * 2009-02-05 2009-03-11 Nanoco Technologies Ltd Encapsulated nanoparticles
EA013570B1 (en) * 2009-02-24 2010-06-30 Ооо "Научно-Производственный Комплекс "Наносистема"" Pharmaceutical composition for treating tuberculosis and diseases mediated by helicobacter pylori based on solid lipid nanoparticles and a method for the treatment of tuberculosis
ES2351756B1 (en) * 2009-07-28 2011-10-05 Universidad Del Pais Vasco LIPID NANOPARTICLES FOR GENE THERAPY.
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
DE102010013064A1 (en) * 2010-03-26 2011-12-15 Gabriele Blume Novel carrier system for the transport of active ingredients into the skin
EP2590625B1 (en) * 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
ES2385080B1 (en) * 2010-12-21 2013-05-10 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea LIPID NANOPARTICLES FOR THE TREATMENT OF EYE DISEASES.
BR112013031553A2 (en) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. compositions, mrna encoding a gland and its use, use of at least one mrna molecule and a vehicle for transfer and use of an mrna encoding for exogenous protein
MX350258B (en) * 2011-07-06 2017-08-31 Novartis Ag Cationic oil-in-water emulsions.
CN107596518B (en) 2012-02-29 2021-04-23 普马特里克斯营业公司 Inhalable dry powder
US9693936B2 (en) 2012-03-07 2017-07-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dispersions in oil of Dead Sea nano sized material preparation and uses therof
CN102670484B (en) * 2012-05-30 2013-06-05 浙江大学 Mannose-modified solid lipid nanoparticle plural gel and preparation method thereof
BR102012015756A2 (en) * 2012-06-26 2014-12-02 Univ Fed De Ouro Preto Ufop PROCEDURE FOR OBTAINING HIGH CONCENTRATIONS OF THE CHEMICAL CONSTITUTE TRANS-PINOCARVILLE ACETATE FOR HYDRODESTILATION OF THE GRAVEOLEN AIR PARTIES AND OBTAINING NANOEMULSIONAL FORMULATIONS.
AU2013351934B2 (en) * 2012-11-30 2018-03-29 Insmed Incorporated Prostacylin compositions and methods for using the same
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
US20140275261A1 (en) 2013-03-15 2014-09-18 Dr. Reddy's Laboratories, Inc. Diclofenac parenteral compositions
CA2927788C (en) 2013-10-25 2022-09-06 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
KR101671864B1 (en) * 2014-08-29 2016-11-04 세종대학교 산학협력단 Cationic emulsion containing iodized oil and use of the cationic emulsion for promoting gene delivery of virus vector
CN107072964A (en) 2014-11-05 2017-08-18 西莱克塔生物科技公司 Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanoparticles comprising RAPALOG
EP3904326A1 (en) 2014-11-18 2021-11-03 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
MX2018011705A (en) 2016-04-01 2019-06-10 Therapeuticsmd Inc Steroid hormone pharmaceutical composition.
BR102017016440A2 (en) * 2017-07-31 2019-03-19 Universidade Federal Do Rio Grande Do Sul COMPOSITION FOR CENTRAL NERVOUS SYSTEM GENE THERAPY, OBTAINING AND USE PROCESS
KR20220002600A (en) 2019-04-29 2022-01-06 인스메드 인코포레이티드 Dry powder composition of treprostinil prodrug and method of use thereof
CN111281982B (en) * 2020-02-19 2023-11-17 深圳厚存纳米药业有限公司 A complex of poloxamer and/or poloxamine combined with lipids
EP4117631A1 (en) 2020-03-11 2023-01-18 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
EP4056038A1 (en) * 2021-03-10 2022-09-14 Basf Se Microparticles containing active substances
CN113350521B (en) * 2021-04-08 2022-11-29 上海大学 LPD nano liposome and preparation method and application thereof
CN113877000B (en) * 2021-10-13 2023-01-24 科笛生物医药(无锡)有限公司 Microsphere composition for injection and application thereof
CN114657147B (en) * 2022-01-27 2023-12-01 安徽智飞龙科马生物制药有限公司 Protective agent for biological material and application thereof
CA3252827A1 (en) * 2022-03-10 2023-09-14 Nammi Therapeutics, Inc. Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
CN115887253B (en) * 2022-10-20 2025-10-24 华南理工大学 A squalane-based nanolipid carrier loaded with ethyl ferulate, and its preparation method and application
CN121398801A (en) * 2023-06-28 2026-01-23 赛诺菲巴斯德有限公司 Uses of glycerides in LNP formulations
CN120346163A (en) * 2024-01-22 2025-07-22 中国科学院过程工程研究所 Oil-in-water emulsion

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0344314A (en) * 1989-07-13 1991-02-26 Nippon Petrochem Co Ltd Hair dyeing assistant for acid dye
DE4039063A1 (en) * 1990-12-07 1992-06-11 Wella Ag HAIR CURING IN THE FORM OF A MICROEMULSION
JPH06508555A (en) * 1991-06-27 1994-09-29 エモリイ・ユニバーシテイ Multiphase emulsion and manufacturing method
JPH06219940A (en) * 1993-01-27 1994-08-09 Shiseido Co Ltd Patch
AU4868396A (en) * 1995-02-22 1996-09-11 Bausch & Lomb Incorporated Skin care composition

Also Published As

Publication number Publication date
KR20020033665A (en) 2002-05-07
KR100374482B1 (en) 2003-03-03
EP1100464A1 (en) 2001-05-23
WO2000006120A1 (en) 2000-02-10
JP2002521423A (en) 2002-07-16

Similar Documents

Publication Publication Date Title
AU5068999A (en) Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
AU5273200A (en) Emulsion vehicle for poorly soluble drugs
AU4818099A (en) Phosphodiesterase-v modulator drugs and their uses
AU1603199A (en) Methods and devices for measuring differential gene expression
AU5020400A (en) Heteroaryloxypyrimidine insecticides and acaricides
AU6876498A (en) Intravesical drug delivery system
AU3068599A (en) Medication infusion set
AU7832498A (en) System for facilitating drug discovery data and method thereof
AU2387997A (en) Stabilized medicaments containing cysteinyl derivatives
AU7538398A (en) Emulsion for well and formation treatment
AU4892897A (en) Phospholipid drug derivatives
AU9646198A (en) Isoquinoline derivative and drug
AU3999699A (en) Targeted liposomal drug delivery system
AU8456198A (en) Taxol emulsion
AU1409100A (en) Drugs
AU2543399A (en) Anticonvulsant drugs and pharmaceutical compositions thereof
AU1502799A (en) Pharmaceutical composition comprising clioquinol and vitamin B12
AU3072500A (en) Rhamnosyl-transferase gene and uses thereof
AU5471600A (en) Variant tlr4 nucleic acid and uses thereof
AU6977898A (en) Strategic marketing system
AU6940998A (en) Phospholipid drug derivatives
AU8382998A (en) P53 influenced gene expression
AU9344398A (en) Tetraether lipid derivatives and liposomes and lipid agglomerates containing tetraetherlipid derivatives, and use thereof
AU3357700A (en) Phenoxypyrimidine insecticides and acaricides
AU6683998A (en) Aortic cannula

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase